{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:55:58Z","timestamp":1792022158832,"version":"4.4.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1038\/nrneph.2016.135","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T01:15:12Z","timestamp":1475457312000},"page":"667-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["The importance of total kidney volume in evaluating progression of polycystic kidney disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Jared J.","family":"Grantham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,3]]},"reference":[{"key":"BFnrneph2016135_CR1","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham, J. J. Clinical practice. Autosomal dominant polycystic kidney disease. N. Engl. J. Med. 359, 1477\u20131485 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2016135_CR2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/ki.1983.51","volume":"23","author":"KA Franz","year":"1983","unstructured":"Franz, K. A. & Reubi, F. C. Rate of functional deterioration in polycystic kidney disease. Kidney Int. 23, 526\u2013529 (1983).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR3","first-page":"128","volume":"4","author":"OZ Dalgaard","year":"1957","unstructured":"Dalgaard, O. Z. Bilateral polycystic disease of the kidneys; a follow-up of 284 patients and their families. Dan. Med. Bull. 4, 128\u2013133 (1957).","journal-title":"Dan. Med. Bull."},{"key":"BFnrneph2016135_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0272-6386(81)80036-4","volume":"1","author":"E Levine","year":"1981","unstructured":"Levine, E. & Grantham, J. J. The role of computed tomography in the evaluation of adult polycystic kidney disease. Am. J. Kidney Dis. 1, 99\u2013105 (1981).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2016135_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.7326\/0003-4819-101-2-238","volume":"101","author":"PA Gabow","year":"1984","unstructured":"Gabow, P. A., Ikle, D. W. & Holmes, J. H. Polycystic kidney disease: prospective analysis of nonazotemic patients and family members. Ann. Intern. Med. 101, 238\u2013247 (1984).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2016135_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/ki.1987.121","volume":"31","author":"JJ Grantham","year":"1987","unstructured":"Grantham, J. J., Geiser, J. L. & Evan, A. P. Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int. 31, 1145\u20131152 (1987).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/ki.2009.128","volume":"76","author":"VE Torres","year":"2009","unstructured":"Torres, V. E. & Harris, P. C. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 76, 149\u2013168 (2009).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.bbadis.2010.11.005","volume":"1812","author":"DP Wallace","year":"2011","unstructured":"Wallace, D. P. Cyclic AMP-mediated cyst expansion. Biochim. Biophys. Acta 1812, 1291\u20131300 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrneph2016135_CR9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone, V. H., 2nd, Wang, X., Harris, P. C. & Torres, V. E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 9, 1323\u20131326 (2003).","journal-title":"Nat. Med."},{"key":"BFnrneph2016135_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1681\/ASN.2007060688","volume":"19","author":"X Wang","year":"2008","unstructured":"Wang, X., Wu, Y., Ward, C. J., Harris, P. C. & Torres, V. E. Vasopressin directly regulates cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 19, 102\u2013108 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2215\/CJN.04560510","volume":"6","author":"E Meijer","year":"2011","unstructured":"Meijer, E. et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 361\u2013368 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/ki.1983.124","volume":"24","author":"KD Gardner Jr","year":"1983","unstructured":"Gardner, K. D. Jr & Evan, A. P. Renal cystic disease induced by diphenylthiazole. Kidney Int. 24, 43\u201352 (1983).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR13","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/ki.1986.116","volume":"29","author":"KD Gardner Jr.","year":"1986","unstructured":"Gardner, K. D. Jr., Evan, A. P. & Reed, W. P. Accelerated renal cyst development in deconditioned germ-free rats. Kidney Int. 29, 1116\u20131123 (1986).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/ki.1987.213","volume":"32","author":"KD Gardner Jr","year":"1987","unstructured":"Gardner, K. D. Jr et al. Endotoxin provocation of experimental renal cystic disease. Kidney Int. 32, 329\u2013334 (1987).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/ki.1991.192","volume":"40","author":"JJ Grantham","year":"1991","unstructured":"Grantham, J. J. Acquired cystic kidney disease. Kidney Int. 40, 143\u2013152 (1991).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000422098","volume":"101","author":"FA Carone","year":"1993","unstructured":"Carone, F. A. & Kanwar, Y. Tubular cell and matrix changes in renal cystic disease. Contrib. Nephrol. 101, 1\u20136 (1993).","journal-title":"Contrib. Nephrol."},{"key":"BFnrneph2016135_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/nrneph.2011.196","volume":"8","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. & Harris, P. C. Polycystic kidney disease in 2011: connecting the dots toward a polycystic kidney disease therapy. Nat. Rev. Nephrol. 8, 66\u201368 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2016135_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ki.2015.207","volume":"88","author":"AC Ong","year":"2015","unstructured":"Ong, A. C. & Harris, P. C. A polycystin-centric view of cyst formation and disease: the polycystins revisited. Kidney Int. 88, 699\u2013710 (2015).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1573402111309010002","volume":"9","author":"T Ecder","year":"2013","unstructured":"Ecder, T. Cardiovascular complications in autosomal dominant polycystic kidney disease. Curr. Hypertens. Rev. 9, 2\u201311 (2013).","journal-title":"Curr. Hypertens. Rev."},{"key":"BFnrneph2016135_CR20","doi-asserted-by":"publisher","unstructured":"Nowak, K. L., Farmer, H., Cadnapaphornchai, M. A., Gitomer, B. & Chonchol, M. Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfw013 (2016).","DOI":"10.1093\/ndt\/gfw013"},{"key":"BFnrneph2016135_CR21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.33549\/physiolres.930324","volume":"52","author":"M Merta","year":"2003","unstructured":"Merta, M. et al. Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease. Physiol. Res. 52, 433\u2013437 (2003).","journal-title":"Physiol. Res."},{"key":"BFnrneph2016135_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/MNH.0b013e3283621510","volume":"22","author":"O Devuyst","year":"2013","unstructured":"Devuyst, O. & Torres, V. E. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. Curr. Opin. Nephrol. Hypertens. 22, 459\u2013470 (2013).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrneph2016135_CR23","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/ki.2012.271","volume":"82","author":"DG Bichet","year":"2012","unstructured":"Bichet, D. G. A defect in vasopressin secretion in autosomal dominant polycystic kidney disease. Kidney Int. 82, 1051\u20131053 (2012).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1523-1755.2003.00755.x","volume":"63","author":"S Nagao","year":"2003","unstructured":"Nagao, S. et al. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease. Kidney Int. 63, 427\u2013437 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR25","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1097\/01.ASN.0000088720.61783.19","volume":"14","author":"D Zheng","year":"2003","unstructured":"Zheng, D. et al. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 14, 2588\u20132595 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2010.06.023","volume":"56","author":"E Meijer","year":"2010","unstructured":"Meijer, E. et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am. J. Kidney Dis. 56, 883\u2013895 (2010).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2016135_CR27","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1093\/ndt\/gfp136","volume":"24","author":"PJ Azurmendi","year":"2009","unstructured":"Azurmendi, P. J. et al. Early renal and vascular changes in ADPKD patients with low-grade albumin excretion and normal renal function. Nephrol. Dial. Transplant. 24, 2458\u20132463 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2016135_CR28","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1681\/ASN.2011010084","volume":"22","author":"A Karihaloo","year":"2011","unstructured":"Karihaloo, A. et al. Macrophages promote cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 22, 1809\u20131814 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR29","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/ki.2012.446","volume":"83","author":"KI Swenson-Fields","year":"2013","unstructured":"Swenson-Fields, K. I. et al. Macrophages promote polycystic kidney disease progression. Kidney Int. 83, 855\u2013864 (2013).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR30","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/ki.2008.397","volume":"74","author":"MA Cadnapaphornchai","year":"2008","unstructured":"Cadnapaphornchai, M. A., McFann, K., Strain, J. D., Masoumi, A. & Schrier, R. W. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int. 74, 1192\u20131196 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR31","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s004670050343","volume":"11","author":"T Seeman","year":"1997","unstructured":"Seeman, T. et al. Blood pressure and renal function in autosomal dominant polycystic kidney disease. Pediatr. Nephrol. 11, 592\u2013596 (1997).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2016135_CR32","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/ki.2013.501","volume":"85","author":"JM Fonseca","year":"2014","unstructured":"Fonseca, J. M. et al. Renal cyst growth is the main determinant for hypertension and concentrating deficit in Pkd1-deficient mice. Kidney Int. 85, 1137\u20131150 (2014).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR33","doi-asserted-by":"publisher","first-page":"e12405","DOI":"10.14814\/phy2.12405","volume":"3","author":"T Saigusa","year":"2015","unstructured":"Saigusa, T. et al. Activation of the intrarenal renin-angiotensin-system in murine polycystic kidney disease. Physiol. Rep. 3, e12405 (2015).","journal-title":"Physiol. Rep."},{"key":"BFnrneph2016135_CR34","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2215\/CJN.00550110","volume":"5","author":"JJ Grantham","year":"2010","unstructured":"Grantham, J. J., Cook, L. T., Wetzel, L. H., Cadnapaphornchai, M. A. & Bae, K. T. Evidence of extraordinary growth in the progressive enlargement of renal cysts. Clin. J. Am. Soc. Nephrol. 5, 889\u2013896 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR35","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1681\/ASN.2006080835","volume":"17","author":"PC Harris","year":"2006","unstructured":"Harris, P. C. et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 17, 3013\u20133019 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR36","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ndt\/gfs417","volume":"28","author":"I Helal","year":"2013","unstructured":"Helal, I. et al. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol. Dial. Transplant. 28, 380\u2013385 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2016135_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1194\/jlr.P042176","volume":"55","author":"J Klawitter","year":"2013","unstructured":"Klawitter, J. et al. Bioactive lipid mediators in polycystic kidney disease. J. Lipid Res. 55, 1139\u20131149 (2013).","journal-title":"J. Lipid Res."},{"key":"BFnrneph2016135_CR38","doi-asserted-by":"publisher","first-page":"e53016","DOI":"10.1371\/journal.pone.0053016","volume":"8","author":"AD Kistler","year":"2013","unstructured":"Kistler, A. D. et al. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS ONE 8, e53016 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrneph2016135_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/sj.ki.5002624","volume":"73","author":"JJ Grantham","year":"2008","unstructured":"Grantham, J. J. et al. Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int. 73, 108\u2013116 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR40","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1681\/ASN.2015050583","volume":"27","author":"CM Heyer","year":"2016","unstructured":"Heyer, C. M. et al. Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27, 2872\u20132884 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR41","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1681\/ASN.2015060648","volume":"27","author":"YH Hwang","year":"2015","unstructured":"Hwang, Y. H. et al. Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27, 1861\u20131868 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR42","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2215\/CJN.09941014","volume":"10","author":"LR Harskamp","year":"2015","unstructured":"Harskamp, L. R. et al. Urinary EGF receptor ligand excretion in patients with autosomal dominant polycystic kidney disease and response to tolvaptan. Clin. J. Am. Soc. Nephrol. 10, 1749\u20131756 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR43","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3892\/mmr.2013.1588","volume":"8","author":"C Liu","year":"2013","unstructured":"Liu, C., Zhang, Y., Yuan, L., Fu, L. & Mei, C. Rosiglitazone inhibits insulin-like growth factor1-induced polycystic kidney disease cell growth and p70S6 kinase activation. Mol. Med. Rep. 8, 861\u2013864 (2013).","journal-title":"Mol. Med. Rep."},{"key":"BFnrneph2016135_CR44","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/j.ajpath.2014.03.007","volume":"184","author":"CI Galarreta","year":"2014","unstructured":"Galarreta, C. I. et al. Tubular obstruction leads to progressive proximal tubular injury and atubular glomeruli in polycystic kidney disease. Am. J. Pathol. 184, 1957\u20131966 (2014).","journal-title":"Am. J. Pathol."},{"key":"BFnrneph2016135_CR45","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1172\/JCI105772","volume":"47","author":"JP Hayslett","year":"1968","unstructured":"Hayslett, J. P., Kashgarian, M. & Epstein, F. H. Functional correlates of compensatory renal hypertrophy. J. Clin. Invest. 47, 774\u2013799 (1968).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2016135_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa0804883","volume":"360","author":"HN Ibrahim","year":"2009","unstructured":"Ibrahim, H. N. et al. Long-term consequences of kidney donation. N. Engl. J. Med. 360, 459\u2013469 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2016135_CR47","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJM197205182862009","volume":"286","author":"NS Bricker","year":"1972","unstructured":"Bricker, N. S. On the pathogenesis of the uremic state. An exposition of the \u201ctrade-off hypothesis\u201d. N. Engl. J. Med. 286, 1093\u20131099 (1972).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2016135_CR48","doi-asserted-by":"publisher","unstructured":"Gansevoort, R. T. et al. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 trial. Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfv422 (2015).","DOI":"10.1093\/ndt\/gfv422"},{"key":"BFnrneph2016135_CR49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2215\/CJN.00910306","volume":"2","author":"VE Torres","year":"2007","unstructured":"Torres, V. E. et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2, 112\u2013120 (2007).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR50","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1681\/ASN.V1181505","volume":"11","author":"BF King","year":"2000","unstructured":"King, B. F. et al. Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 11, 1505\u20131511 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR51","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1046\/j.1523-1755.2000.00433.x","volume":"58","author":"C Sise","year":"2000","unstructured":"Sise, C. et al. Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography. Kidney Int. 58, 2492\u20132501 (2000).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR52","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2215\/CJN.00330705","volume":"1","author":"JJ Grantham","year":"2006","unstructured":"Grantham, J. J., Chapman, A. B. & Torres, V. E. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin. J. Am. Soc. Nephrol. 1, 148\u2013157 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR53","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham, J. J. et al. Volume progression in polycystic kidney disease. N. Engl. J. Med. 354, 2122\u20132130 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2016135_CR54","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman, A. B. et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 7, 479\u2013486 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR55","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal, M. V. et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J. Am. Soc. Nephrol. 26, 160\u2013172 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR56","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ki.2015.71","volume":"88","author":"H Bhutani","year":"2015","unstructured":"Bhutani, H. et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 88, 146\u2013151 (2015).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR57","first-page":"B119","volume":"63","author":"RD Perrone","year":"2014","unstructured":"Perrone, R. D. et al. Qualification of total kidney volume as a prognostic biomarker for use in clinical trials evaluating patients with polycystic kidney disease. Am. J. Kidney Dis. 63, B119 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2016135_CR58","unstructured":"U.S. Department of Health & Human Services, Food & Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry Expedited Programs for Serious Conditions \u2013 Drugs and Biologics http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm358301.pdf (2014)."},{"key":"BFnrneph2016135_CR59","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1093\/ndt\/gfp010","volume":"24","author":"JV Bonventre","year":"2009","unstructured":"Bonventre, J. V. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol. Dial. Transplant. 24, 3265\u20133268 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2016135_CR60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00467-006-0146-y","volume":"21","author":"H Trachtman","year":"2006","unstructured":"Trachtman, H. et al. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr. Nephrol. 21, 989\u2013994 (2006).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2016135_CR61","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830\u2013840 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2016135_CR62","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra, A. L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820\u2013829 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2016135_CR63","first-page":"1259","volume":"368","author":"VE Torres","year":"2013","unstructured":"Torres, V. E., Gansevoort, R. T. & Czerwiec, F. S. Tolvaptan in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 368, 1259 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2016135_CR64","doi-asserted-by":"publisher","unstructured":"Grantham, J. J. et al. Tolvaptan suppresses monocyte chemotactic protein-1 in autosomal-dominant polycystic kidney disease. Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfw060 (2016).","DOI":"10.1093\/ndt\/gfw060"},{"key":"BFnrneph2016135_CR65","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier, R. W. et al. Blood pressure in early autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2255\u20132266 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2016135_CR66","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","volume":"382","author":"A Caroli","year":"2013","unstructured":"Caroli, A. et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 382, 1485\u20131495 (2013).","journal-title":"Lancet"},{"key":"BFnrneph2016135_CR67","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1053\/j.ajkd.2013.10.011","volume":"63","author":"E Meijer","year":"2014","unstructured":"Meijer, E. et al. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 63, 446\u2013455 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2016135_CR68","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2215\/CJN.08350813","volume":"9","author":"MA Cadnapaphornchai","year":"2014","unstructured":"Cadnapaphornchai, M. A. et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 9, 889\u2013896 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR69","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2796.2006.01743.x","volume":"261","author":"VE Torres","year":"2007","unstructured":"Torres, V. E. & Harris, P. C. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J. Intern. Med. 261, 17\u201331 (2007).","journal-title":"J. Intern. Med."},{"key":"BFnrneph2016135_CR70","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","volume":"385","author":"AC Ong","year":"2015","unstructured":"Ong, A. C., Devuyst, O., Knebelmann, B., Walz, G. & ERA-EDTA Working Group for Inherited Kidney Diseases Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 385, 1993\u20132002 (2015).","journal-title":"Lancet"},{"key":"BFnrneph2016135_CR71","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.06300615","volume":"11","author":"VE Torres","year":"2016","unstructured":"Torres, V. E. et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin. J. Am. Soc. Nephrol. 11, 803\u2013811 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR72","doi-asserted-by":"publisher","unstructured":"Irazabal, M. V. et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfw294 (2016).","DOI":"10.1093\/ndt\/gfw294"},{"key":"BFnrneph2016135_CR73","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00467-014-2882-8","volume":"30","author":"JJ Grantham","year":"2015","unstructured":"Grantham, J. J. Rationale for early treatment of polycystic kidney disease. Pediatr. Nephrol. 30, 1053\u20131062 (2015).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2016135_CR74","unstructured":"Cardiovascular and Renal Drugs Advisory Committee Tolvaptan: slowing progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM364583.pdf (2013)."},{"key":"BFnrneph2016135_CR75","first-page":"75","volume":"4","author":"KR Lee","year":"1981","unstructured":"Lee, K. R., Grantham, J. J. & Cook, P. N. Volume estimation from computed tomography for polycystic kidney disease. Automedica 4, 75\u201379 (1981).","journal-title":"Automedica"},{"key":"BFnrneph2016135_CR76","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF02927815","volume":"3","author":"HS Thomsen","year":"1981","unstructured":"Thomsen, H. S., Madsen, J. K., Thaysen, J. H. & Damgaard-Petersen, K. Volume of polycystic kidneys during reduction of renal function. Urol. Radiol 3, 85\u201389 (1981).","journal-title":"Urol. Radiol"},{"key":"BFnrneph2016135_CR77","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","volume":"68","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti, P. et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 68, 206\u2013216 (2005).","journal-title":"Kidney Int."},{"key":"BFnrneph2016135_CR78","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2215\/CJN.02251205","volume":"1","author":"L Antiga","year":"2006","unstructured":"Antiga, L. et al. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin. J. Am. Soc. Nephrol. 1, 754\u2013760 (2006).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR79","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2215\/CJN.03780410","volume":"6","author":"MA Cadnapaphornchai","year":"2011","unstructured":"Cadnapaphornchai, M. A., Masoumi, A., Strain, J. D., McFann, K. & Schrier, R. W. Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin. J. Am. Soc. Nephrol. 6, 369\u2013376 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2016135_CR80","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10157-011-0428-y","volume":"15","author":"S Tokiwa","year":"2011","unstructured":"Tokiwa, S., Muto, S., China, T. & Horie, S. The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin. Exp. Nephrol. 15, 539\u2013545 (2011).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrneph2016135_CR81","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s10157-012-0611-9","volume":"16","author":"E Higashihara","year":"2012","unstructured":"Higashihara, E. et al. Renal disease progression in autosomal dominant polycystic kidney disease. Clin. Exp. Nephrol. 16, 622\u2013628 (2012).","journal-title":"Clin. Exp. Nephrol."},{"key":"BFnrneph2016135_CR82","doi-asserted-by":"publisher","first-page":"e92232","DOI":"10.1371\/journal.pone.0092232","volume":"9","author":"D Chen","year":"2014","unstructured":"Chen, D. et al. Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease. PLoS ONE 9, e92232 (2014).","journal-title":"PLoS ONE"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2016.135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2016.135","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2016.135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T05:18:15Z","timestamp":1692508695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2016.135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,3]]},"references-count":82,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["BFnrneph2016135"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2016.135","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726818770.793555204","asserted-by":"object"}]},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,3]]},"assertion":[{"value":"3 October 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J.G and V.E.T have consulted for and received research grants from Otsuka Pharmaceutical Development and Commercialization, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}